Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

被引:95
|
作者
Kanakis, George [1 ]
Kaltsas, Gregory [1 ]
机构
[1] Univ Athens, Sch Med, GR-11527 Athens, Greece
关键词
Neuroendocrine tumours; Chromogranins; Neuron-Specific Enolase (NSE); Pancreatic polypeptide (PP); 5-HIAA; Carcinoid; Insulinoma; Gastrinoma; VIPoma; Glucagonoma; Somatostatinoma; NEURON-SPECIFIC ENOLASE; PROGASTRIN-RELEASING PEPTIDE; ZOLLINGER-ELLISON-SYNDROME; PLASMA CHROMOGRANIN-A; PANCREATIC-POLYPEPTIDE; 5-HYDROXYINDOLEACETIC ACID; GASTROINTESTINAL-TRACT; PROGNOSTIC MARKERS; ENDOCRINE TUMORS; FOLLOW-UP;
D O I
10.1016/j.bpg.2012.12.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Biochemical markers are applied in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) for diagnostic, prognostic or predictive purposes. Chromogranin A is the most important general marker and it is recommended to be measured in every patient with a suspected NET, whereas Neuron Specific Enolase is elevated mainly in poorly differentiated NETs. Pancreatic Polypeptide is used in the diagnosis of pancreatic non-functioning NETs, whereas Chorionic Gonadotrophin has an adjunctive role. In the case of functioning tumours, specific markers should be sought and monitored during follow up. Endogenous hyperinsulinemia is suggested in the presence of non-suppressible insulin and proinsulin levels during hypoglycemia, whereas high fasting or stimulated gastrin levels along with elevated gastric acid output are diagnostic for the Zollinger-Ellison syndrome. Glucagon, vasoactive intestinal polypeptide (VIP) and somatostatin are markers for glucagonoma, VIP-oma and somatostatinoma syndromes respectively. In case of ectopic paraneoplastic syndrome, the relevant hormone serves as a diagnostic and prognostic marker. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:791 / 802
页数:12
相关论文
共 50 条
  • [1] Predictive Markers of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
    Issaeva, S.
    Khalimova, Z.
    Safarova, M.
    Gumarova, A.
    Yuldashev, A.
    NEUROENDOCRINOLOGY, 2018, 106 : 89 - 89
  • [2] Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)
    Enrique Grande
    Juan José Díez
    Vanessa Pachón
    Alfredo Carrato
    Clinical and Translational Oncology, 2010, 12 : 481 - 492
  • [3] Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)
    Grande, Enrique
    Jose Diez, Juan
    Pachon, Vanessa
    Carrato, Alfredo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (07): : 481 - 492
  • [4] Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Kizilgul, Muhammed
    Delibasi, Tuncay
    TRANSLATIONAL GASTROINTESTINAL CANCER, 2015, 4 (01) : 39 - 56
  • [5] Recommended parameters for pathology reporting of gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
    Rasheed, Imran
    Meng, Looi Lai
    Talib, Arni
    MALAYSIAN JOURNAL OF PATHOLOGY, 2018, 40 (01) : 79 - 82
  • [6] Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Preface
    de Herder, Wouter W.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2012, 26 (06) : 689 - 690
  • [7] Cutaneous Metastasis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-Nets)
    Dhingra, Rohit
    Tse, Julie Y.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2018, 19 (05): : 258 - 260
  • [8] mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
    Zanini, Sara
    Renzi, Serena
    Giovinazzo, Francesco
    Bermano, Giovanna
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [9] GEP-NETs UPDATE Biotherapy for neuroendocrine tumours
    Alonso-Gordoa, T.
    Capdevila, J.
    Grande, E.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (01) : R31 - R46
  • [10] PROGNOSTIC FACTORS INFLUENCING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETs)
    Arrazubi, Virginia
    Sala, Marian
    Galve, Elena
    Teresa Perez-Hoyos, Maria
    Hinojo, Carmen
    Etxezarraga, Carmen
    Gonzalez, Carmen
    Gomez, Pilar
    Martinez del Prado, Purificacion
    ANNALS OF ONCOLOGY, 2011, 22 : v69 - v69